Castration-resistant Prostate Cancer Clinical Trials

176 clinical trials for Castration-resistant Prostate Cancer across international registries, including 43 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• Study of Oral MRT-2359 With Apalutamide in Prostate Cancer — RECRUITING · PHASE2
• Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial — RECRUITING · PHASE2
• Study of DCC-2812 in Participants With Advanced Genitourinary Cancers — RECRUITING · PHASE1
• A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types — RECRUITING · PHASE1
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors — RECRUITING · PHASE1
• A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer — RECRUITING · PHASE1
• YS247 (Neoantigen-Pulsed DC Vaccine) for Metastatic Prostate Cancer — RECRUITING · PHASE1
• Bipolar Androgen Therapy + Carboplatin in mCRPC — RECRUITING · PHASE2
• A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC — RECRUITING · PHASE1
• 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors — RECRUITING · PHASE1
• Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer — RECRUITING · PHASE2
• GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy — RECRUITING · PHASE1
• Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy — RECRUITING · PHASE4
• ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials — RECRUITING
• A PHASE 1/2 FIRST-TIME-IN-HUMAN, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION STUDY OF GSK5458514 PSMA TARGETING T CELL ENGAGER ALONE OR IN COMBINATION WITH OTHER ANTI-CANCER AGENTS IN ADULT PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE1
• A MULTINATIONAL, MULTICENTER, PROSPECTIVE, RANDOMIZED, CONTROLLED, OPENLABEL, PHASE 3 STUDY OF LUTETIUM (177LU) ROSOPATAMAB TETRAXETAN IN COMBINATION WITH STANDARD OF CARE VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) AFTER ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI) TREATMENT — RECRUITING · PHASE3
• A PHASE 3, TWO-PART, RANDOMIZED, OPEN-LABEL, ADAPTIVE STUDY COMPARING BMS- 986365 VERSUS INVESTIGATOR'S CHOICE OF THERAPY COMPRISING EITHER DOCETAXEL OR SECOND ANDROGEN RECEPTOR PATHWAY INHIBITOR (ARPI), IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) - RECHARGE — RECRUITING · PHASE3
• A RANDOMIZED PHASE III CLINICAL TRIAL FOR THE ADDITION OF DOCETAXEL TO ANDROGEN RECEPTOR PATHWAY INHIBITORS IN PATIENTS WITH METASTATIC CASTRATION SENSITIVE PROSTATE CANCER AND SUBOPTIMAL PSA RESPONSE (TRIPLE-SWITCH) — RECRUITING · PHASE3
• Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer — RECRUITING · PHASE3
• Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study — RECRUITING · PHASE1
• SATISFACTION: A PHASE I/II, OPEN-LABEL, MULTI-CENTER STUDY OF [225AC]AC-PSMA-R2 IN MEN WITH HEAVILY PRE-TREATED PSMA POSITIVE METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) WITH OR WITHOUT PRIOR 177LU-LABELLED PSMA-TARGETED RADIOLIGAND THERAPY — RECRUITING · PHASE1
• OPTION-DDR: A RANDOMIZED PHASE III TRIAL INVESTIGATING PLATINUM AND TAXANE CHEMOTHERAPY IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER PATIENTS WITH ALTERATIONS IN DNA DAMAGE RESPONSE (DDR) GENES — RECRUITING · PHASE3
• Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer — RECRUITING · NA
• Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone — RECRUITING
• [(A)C-225]-PSMA-62 PHASE I/II (C)LINICAL TRIAL TO (CHARACTERIZE (E)FFICACY, SAFETY, TO(L)ERABILITY, AND DOSIMETRY IN BIOCHEMICALLY RECURRENT AND METASTATIC CASTRATION RESISTANT PROSTATE CANCER (ACCEL) — RECRUITING · PHASE1
• A PHASE 1 OPEN-LABEL, FIRST-IN-HUMAN, MULTI-CENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTITUMOR ACTIVITY OF 225ACPSMA-TRILLIUM IN PARTICIPANTS WITH ADVANCED METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE1
• AN INTERNATIONAL PROSPECTIVE OPEN-LABEL, MULTI-CENTER, RANDOMIZED, NON-COMPARATIVE PHASE II STUDY OF LUTETIUM [177LU] VIPIVOTIDE TETRAXETAN (AAA617) ALONE AND LUTETIUM [177LU] VIPIVOTIDE TETRAXETAN (AAA617) IN COMBINATION WITH ANDROGEN RECEPTOR PATHWAY INHIBITORS IN PATIENTS WITH PSMA PET SCAN POSITIVE CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE2
• A PHASE I/II STUDY OF 177LU-HTK03170 IN METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER SUBJECTS WITH PROSTATE-SPECIFIC MEMBRANE ANTIGEN-POSITIVE DISEASE — RECRUITING · PHASE1
• TALAPRO 3: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN WITH DDR GENE MUTATED METASTATIC CASTRATION-SENSITIVE PROSTRATE CANCER — RECRUITING · PHASE3
• PSMAFORE: A PHASE III, OPEN-LABEL, MULTI-CENTER, RANDOMIZED STUDY COMPARING 177LU-PSMA-617 VS. A CHANGE OF ANDROGEN RECEPTOR-DIRECTED THERAPY IN THE TREATMENT OF TAXANE NAÏVE MEN WITH PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER — RECRUITING · PHASE3
• SPLASH: STUDY EVALUATING METASTATIC CASTRATE RESISTANT PROSTATE CANCER TREATMENT USING 177LU-PNT2002 THERAPY AFTER SECOND-LINE HORMONAL TREATMENT — RECRUITING
• DETECTION AND MONITORING OF METASTASIS BY 18F-DCFPYL (PYL) PET/CT IN SUBJECTS STARTING ENZALUTAMIDE FOR UNTREATED CASTRATION RESISTANT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING — RECRUITING
• A PHASE 3, RANDOMIZED, OPEN-LABEL, CONTROLLED STUDY OF CABOZANTINIB (XL184) IN COMBINATION WITH ATEZOLIZUMAB VS SECOND NOVEL HORMONAL THERAPY (NHT) IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE3
• A PHASE 3, RANDOMIZED OPEN-LABEL STUDY OF PEMBROLIZUMAB (MK-3475) PLUS OLAPARIB VERSUS ABIRATERONE ACETATE OR ENZALUTAMIDE IN PARTICIPANTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) WHO ARE UNSELECTED FOR HOMOLOGOUS RECOMBINATION REPAIR DEFECTS AND HAVE FAILED PRIOR TREATMENT WITH ONE NEXT-GENERATION HORMONAL AGENT (NHA) AND CHEMOTHERAPY (KEYLYNK-010) — RECRUITING · PHASE3
• VISION: AN INTERNATIONAL, PROSPECTIVE, OPEN LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF 177LU-PSMA-617 IN THE TREATMENT OF PATIENTS WITH PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE3
• SAFETY AND TOLERABILITY ANALYSIS OF COMBINING DESMOPRESSIN WITH DOCETAXEL FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING
• A PHASE 2 STUDY OF NIVOLUMAB IN COMBINATION WITH EITHER RUCAPARIB, DOCETAXEL, OR ENZALUTAMIDE IN MEN WITH CASTRATION-RESISTANT METASTATIC PROSTATE CANCER (CHECKMATE 9KD: CHECKPOINT PATHWAY AND NIVOLUMAB CLINICAL TRIAL EVALUATION 9KD) — RECRUITING · PHASE2
• A PHASE III, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH ENZALUTAMIDE VERSUS ENZALUTAMIDE ALONE IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER AFTER FAILURE OF AN ANDROGEN SYNTHESIS INHIBITOR AND FAILURE OF, INELIGIBILITY FOR, OR REFUSAL OF A TAXANE REGIMEN — RECRUITING · PHASE3
• A PHASE II STUDY OF PALBOCICLIB, A CDK4/6 INHIBITOR, IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER — RECRUITING · PHASE2
• A PHASE 1/2 OPEN-LABEL STUDY TO ASSESS THE SAFETY, PHARMACOKINETICS, AND ANTI-TUMOR ACTIVITY OF ORAL EPI-506 IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER. — RECRUITING · PHASE1
• A PHASE 3 RANDOMIZED, PLACEBO-CONTROLLED DOUBLE-BLIND STUDY OF JNJ-56021927 IN COMBINATION WITH ABIRATERONE ACETATE AND PREDNISONE VERSUS ABIRATERONE ACETATE AND PREDNISONE IN SUBJECTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) — RECRUITING · PHASE3
• PHASE III TRIAL OF ENZULUTAMIDE (NSC#766085) VERSUS ENZALUTAMIDE, ABIRATERONE AND PREDNISONE FOR CASTRATION RESISTANT METASTATIC PROSTATE CANCER — RECRUITING · PHASE3
• Randomized, Double-Blind, Phase 3 Trial to Compare the Efficacy of Ipilimumab vs Placebo in Asymptomatic or Minimally Symptomatic Patients with Metastatic Chemotherapy-Naïve Castration Resistant Prostate Cancer (Document Control Number : v3.0 930038662 2.0) + Administrative Letters 01 (version 1.0 dated 02-Jun-10) and 02 (version 1.0 dated 04-Nov-10) — TERMINATED · PHASE3
• SPECTRE A single arm Phase II study to test if adding statins to hormone treatment will result in better cancer control in patients with hormone resistant prostate cancer. — COMPLETED · PHASE2
• CESAR Study in Prostrate Cancer with Temsirolimus added to standard Docetaxel therapy (CEPTAS) — COMPLETED · PHASE2
• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of ARN-509 in Men with Non-Metastatic (M0) Castration-Resistant Prostate Cancer — TERMINATED · PHASE3
• Clinical Study of Safety and Efficacy of Enhanced PSMA CAR- T in Refractory CRPC — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer — NOT_YET_RECRUITING · PHASE2
• Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search